Skip to main content
. Author manuscript; available in PMC: 2013 Jul 29.
Published in final edited form as: J Pharm Sci. 2011 Sep 8;101(1):31–47. doi: 10.1002/jps.22742

Table 4.

Vaccine formulations prepared to test the potency of dry powder rPA vaccines.

Groups rPA Dose
(μg)
Route Adjuvant
1 liquid, rPA alone 30 Nasal NONE
2 liquid, rPA and C48/80 30 Nasal C48/80, 120 μg
3 Powder (prepared Aug.09) 30 Nasal C48/80, 120 μg
4 Powder (prepared Sep.07) 30 Nasal C48/80, 120 μg
5 liquid, IM 30 IM C48/80, 120 μg